• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Cancer: Allegro Diagnostics hunts lung cancer’s “canary in the coal mine”

Cancer: Allegro Diagnostics hunts lung cancer’s “canary in the coal mine”

August 15, 2011 By Arezu Sarvestani

Avrum Spira in the clinic

Dr. Avrum Spira in the clinic

If Allegro Diagnostics’ clinical trials go as planned, the Maynard, Mass.-based company will be on its way to commercializing a test to detect the "canary in the coal mine" of the planet’s deadliest cancer: Early-stage lung cancer.

With a patented molecular diagnostic assay, Allegro co-founder and Boston University associate professor Avrum Spira has garnered over $3.5 million in funding from the National Institutes of Health and $8.9 million from investors.

Shortly after being named BU’s Innovator of the Year for 2011, Spira took time to speak with MassDevice about the foundation of the company, its progress toward getting the test to market and the future of cancer diagnostics.

Avrum Spira

Avrum Spira

MassDevice: What was the inspiration for Allegro Diagnostics?

Avrum Spira: For the last 10 years, my lab over at the [Boston University] medical school has been focused on developing ways to diagnose lung cancer at an earlier stage.

Lung cancer is a deadly disease; it’s the number one cause of cancer death in the United States and in the world, and as a pulmonary doctor I always see tremendous numbers of cases of patients who are dying.

One of the main reasons they die of the disease is we don’t detect it at an early stage. We pick it up when it’s already advanced and the patients aren’t going to survive very much longer. So clearly there was a clinical need to develop the tools to identify smokers who are mostly likely to develop the disease and pick it up at an early and potentially curable stage.

That was really the motivation for all the molecular biomarker work that our group has been pursuing for the past 10 years.

About five years ago, we had a major breakthrough in our research, where we identified a molecular signature in airway cells, in the cells that line your windpipe. What was interesting is that signature could distinguish a smoker who was going on to get lung cancer from one who was not.

One of the reasons it’s hard to diagnose lung cancer early is the cancer arises deep in your lungs, so it’s very hard to get to that without opening up your chest in surgery. These cells that line your windpipe are almost like a canary in a coal mine.

By looking at the genetic molecular changes in those cells, cells that look normal under a microscope, and yet the molecular changes in those cells provide us with a signature that you’re either on the way to getting cancer or not, to give us an opportunity to identify the disease at an early and potentially curable stage.

That was a major breakthrough for us. We published that in a very high-impact journal and the patents that went along with that are essentially what gave rise to Allegro Diagnostics. The idea at that point, in 2007, was we now believe that we have a biomarker that can impact clinical practice, can help diagnose the disease early – how do we get it into the clinic?

That’s when Boston University came up to us and said, "Hey, you’ve got some patents that are commercializable, we can give you the help to take this biomarker from an academic project to move it into the clinic," and that’s essentially what Allegro Diagnostics is trying to do.

MassDevice: What is Allegro working on now?

AS: We’re in the middle of a large clinical trial to validate this 80-gene biomarker. What we have is an assay that measures the activity level of a set of genes in the cells in the windpipe. That’s now being validated on about 800 smokers who are getting bronchoscopy, which is a procedure that’s been used to diagnose lung cancer in people who have abnormalities on their imaging studies of their chest.

So what they’re to do is see if our biomarker accurately distinguishes those people who truly have lung cancer from those who don’t. If it does, it can serve as an adjunct procedure to bronchoscopy, so people getting that procedure can also have this molecular study done to improve the accuracy of diagnosing lung cancer in that setting.

I should mention bronchoscopy doesn’t do a very good job on its own in detecting lung cancer. That’s why we need to have additional molecular tools added on.

MassDevice: So this doesn’t replace bronchoscopy, it adds on to it?

AS: It actually relies on the procedure to get the cells in the windpipe. So these are patients who are going to get that procedure anyway, as an initial diagnostic test. That test has a very relatively low sensitivity for early-stage lung cancer, because it can’t get all the way out deep into the lung and it has a very hard time in finding cancer cells.

Our test is essentially piggy-backing on that study. We’ll just brush the cells in the windpipe on the way out, at the end of the procedure, look at the molecular changes there, and we’ll tell you whether that abnormality on that CT scan is cancer or not.

That can help the clinician then decide, do I go to surgery next or can I just watch the patient with a routine CT scanner? That’s the specific clinical indication that we’re looking for.

MassDevice: What’s the next step?

AS: The next step is to complete the trial. It’s about halfway through. We’re hoping, within the next 12 months, to finish the quota of patients, run the biomarker assay, validate the accuracy and then hopefully offer the test, maybe initially as a CLIA, but eventually go through the FDA and get this as a true FDA -approved biomarker into the clinic.

We do have additional biomarkers in the R&D phase back in our lab. Specifically, we’re trying to move biomarkers to a less-invasive site.

We believe that the cells that line the nose and potentially the mouth could also serve as this "canary in the coal mine," that molecular changes there might tell whether a smoker’s developing lung cancer.

We’re beginning to explore that in a very early discovery phase. Hopefully that’s something Allegro will take on as its next product.

MassDevice: What do you see for the future in molecular diagnostics?

AS: I think, in the next five to 10 years, we’re going to see a number of these types of tools make it into the clinic and impact care. It’s exciting as a clinician, because these are diseases that we have done very little for in 20, 30 years, and we’re at a sort of breaking point now of a new molecular revolution in how we manage these diseases clinically. It’s very exciting.

Filed Under: Diagnostics, Genomics/Molecular Diagnostics, News Well, Oncology Tagged With: Allegro Diagnostics, Boston University, MassDevice Q&A, Pulmonary

In case you missed it

  • ResMed expects steady growth over the next year
  • Ambu is letting go of 200 employees
  • Medtronic has Class I recall for low-shock risk in ICDs
  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance
  • Surgalign settles on OEM business sale, posts Q2 earnings miss
  • Alcon lowers its 2022 forecast amid strong dollar

RSS From Medical Design & Outsourcing

  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy